Healthcare Industry News: radiosurgery
News Release - July 25, 2011
Five Leading Academic Hospitals Install the CyberKnife System for Dedicated RadiosurgeryAdoption Demonstrates Continued Demand for Dedicated Whole Body Stereotactic radiosurgery Systems at World's Most Renowned Cancer Centers
SUNNYVALE, Calif., July 25, 2011 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq:ARAY ), the premier radiation oncology company, announced today installation of the CyberKnife® Robotic radiosurgery System at five renowned academic oncology centers in Europe and the United States, including the Penn Medicine at Pennsylvania Hospital in Philadelphia, PA; The Royal Marsden Hospital in London, England; The Barts Cancer Center at St. Bartholomew's Hospital in London, England; Charite University in Berlin, Germany; and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch in Gliwice, Poland. Backed by solid clinical evidence for a wide range of treatment applications, including prostate and lung cancer, the CyberKnife System empowers these leading centers to offer minimally invasive radiosurgical treatment options for patients with even the most complex tumors.
"Adoption of the CyberKnife System at these prestigious academic medical centers known for offering patients the most innovative and state-of-the-art options for cancer treatment is further validation of CyberKnife as the premier system for dedicated radiosurgery," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "Accuray is proud to work with a growing number of academic centers around the world that are advancing the use of radiosurgery beyond intracranial applications to treat patients with a wide range of indications and breaking new ground in both research and patient care."
"We chose the CyberKnife System because of the scientific evidence demonstrating the technology's ability to treat a broad range of tumors anywhere in the body. This functionality is simply not possible with other technologies, including hybrid radiation therapy systems," stated Prof. Dr. Volker Budach and Prof. Dr. Peter Vajkoczy, respective heads of the departments of Radiation Oncology and Neurosurgery at Charite University in Berlin "Our mission at Charite is to provide patients with the most personalized care when treating cancer. The CyberKnife System, combined with our physicians' expertise, allows us to better tailor our treatments using the most advanced technology in radiosurgery."
Accuray Incorporated (Nasdaq:ARAY ), based in Sunnyvale, Calif., is the premier radiation oncology company. Accuray develops, manufactures and sells personalized, best-in-class treatment solutions that revolve around the patient. Accuray's game-changing technologies – the CyberKnife System and TomoTherapy Systems – set the standard of care with the aim of helping patients live longer, better lives. To date, more than 200,000 patients worldwide have been treated using the company's technologies and more than 550 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, clinical research and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on May 10, 2011 and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsHong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact(R) System and ClearRT(TM) Helical Fan-Beam kVCT Imaging
Accuray Expands CyberKnife(R) System Versatility with Integration of RaySearch's RayStation Treatment Planning System
RayStation Latest Release, Now with Support for Accuray's CyberKnife(R) System